Western blotting results demonstrated that compared to the Control group, the expression of P-AMPK in the NAFLD group (n = 3) was significantly inhibited (p < 0.05), whereas the expressions of SREBP-1c and FASN were significantly increased (p < 0.05) (Figure 7). This evidence concerns the gene SREBF1 and metabolic dysfunction-associated steatotic liver disease.